Trials / Unknown
UnknownNCT04552977
A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Shandong Cancer Hospital and Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a one arm, open, single center phase II study. The main purpose of this study was to evaluate the efficacy and safety of fluzoparil combined with temozolomide in patients with recurrent glioblastoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fluzoparil | a PARP1 inhibitor |
| DRUG | temozolomide | an alkylating chemotherapeutic agent |
Timeline
- Start date
- 2020-09-01
- Primary completion
- 2021-08-01
- Completion
- 2022-08-01
- First posted
- 2020-09-17
- Last updated
- 2020-09-17
Source: ClinicalTrials.gov record NCT04552977. Inclusion in this directory is not an endorsement.